Literature DB >> 22013079

Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells.

Yue Liu1, Fei Ye, Kazunari Yamada, Jonathan L Tso, Yibei Zhang, David H Nguyen, Qinghua Dong, Horacio Soto, Jinny Choe, Anna Dembo, Hayley Wheeler, Ascia Eskin, Ingrid Schmid, William H Yong, Paul S Mischel, Timothy F Cloughesy, Harley I Kornblum, Stanley F Nelson, Linda M Liau, Cho-Lea Tso.   

Abstract

Glioblastoma stem cells (GSC) express both radial glial cell and neural crest cell (NCC)-associated genes. We report that endothelin 3 (EDN3), an essential mitogen for NCC development and migration, is highly produced by GSCs. Serum-induced proliferative differentiation rapidly decreased EDN3 production and downregulated the expression of stemness-associated genes, and reciprocally, two glioblastoma markers, EDN1 and YKL-40 transcripts, were induced. Correspondingly, patient glioblastoma tissues express low levels of EDN3 mRNA and high levels of EDN1 and YKL-40 mRNA. Blocking EDN3/EDN receptor B (EDNRB) signaling by an EDNRB antagonist (BQ788), or EDN3 RNA interference (siRNA), leads to cell apoptosis and functional impairment of tumor sphere formation and cell spreading/migration in culture and loss of tumorigenic capacity in animals. Using exogenous EDN3 as the sole mitogen in culture does not support GSC propagation, but it can rescue GSCs from undergoing cell apoptosis. Molecular analysis by gene expression profiling revealed that most genes downregulated by EDN3/EDNRB blockade were those involved in cytoskeleton organization, pause of growth and differentiation, and DNA damage response, implicating the involvement of EDN3/EDNRB signaling in maintaining GSC migration, undifferentiation, and survival. These data suggest that autocrine EDN3/EDNRB signaling is essential for maintaining GSCs. Incorporating END3/EDNRB-targeted therapies into conventional cancer treatments may have clinical implication for the prevention of tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22013079      PMCID: PMC3245317          DOI: 10.1158/1541-7786.MCR-10-0563

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  Ontogeny of endothelins-1 and -3, their receptors, and endothelin converting enzyme-1 in the early human embryo.

Authors:  M Brand; J M Le Moullec; P Corvol; J M Gasc
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

2.  The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells.

Authors:  M M Pao; M Tsutsumi; G Liang; E Uzvolgyi; F A Gonzales; P A Jones
Journal:  Hum Mol Genet       Date:  2001-04-15       Impact factor: 6.150

3.  Stimulation of endothelin B receptors in astrocytes induces cAMP response element-binding protein phosphorylation and c-fos expression via multiple mitogen-activated protein kinase signaling pathways.

Authors:  S Schinelli; P Zanassi; M Paolillo; H Wang; A Feliciello; V Gallo
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  The neural crest population responding to endothelin-3 in vitro includes multipotent cells.

Authors:  J G Stone; L I Spirling; M K Richardson
Journal:  J Cell Sci       Date:  1997-07       Impact factor: 5.285

6.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

7.  Effects of TNF-alpha on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs.

Authors:  C Mitaka; Y Hirata; K Ichikawa; K Yokoyama; T Emori; K Kanno; K Amaha
Journal:  Am J Physiol       Date:  1994-10

8.  SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

Authors:  Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

9.  Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells.

Authors:  De Jun Sun; Ying Liu; Dong Cheng Lu; Woonbong Kim; Je Ho Lee; Jonathan Maynard; Albert Deisseroth
Journal:  Hum Pathol       Date:  2007-04-18       Impact factor: 3.466

10.  Cloning and functional expression of human endothelin-converting enzyme cDNA.

Authors:  K Shimada; Y Matsushita; K Wakabayashi; M Takahashi; A Matsubara; Y Iijima; K Tanzawa
Journal:  Biochem Biophys Res Commun       Date:  1995-02-15       Impact factor: 3.575

View more
  21 in total

1.  Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.

Authors:  Sun-Jin Kim; Ho Jeong Lee; Mark Seungwook Kim; Hyun Jin Choi; Junqin He; Qiuyu Wu; Kenneth Aldape; Jeffrey S Weinberg; W K Alfred Yung; Charles A Conrad; Robert R Langley; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2015-06-23       Impact factor: 12.531

Review 2.  Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Authors:  Laura Rosanò; Francesca Spinella; Anna Bagnato
Journal:  Nat Rev Cancer       Date:  2013-07-25       Impact factor: 60.716

3.  CD133 and BMI1 expressions and its prognostic role in primary glioblastoma.

Authors:  M K Sibin; C H Lavanya; Dhananjaya I Bhat; Narasinga Rao; N Geethashree; W Vibhuti; G K Chetan
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

4.  Notch1-STAT3-ETBR signaling axis controls reactive astrocyte proliferation after brain injury.

Authors:  Matthew D LeComte; Issei S Shimada; Casey Sherwin; Jeffrey L Spees
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

5.  Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.

Authors:  Francesca Spinella; Valentina Caprara; Valeriana Di Castro; Laura Rosanò; Roberta Cianfrocca; Pier Giorgio Natali; Anna Bagnato
Journal:  J Mol Med (Berl)       Date:  2012-09-11       Impact factor: 4.599

6.  Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

Authors:  Ho Jeong Lee; Masaki Hanibuchi; Sun-Jin Kim; Hyunkyung Yu; Mark Seungwook Kim; Junqin He; Robert R Langley; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neuro Oncol       Date:  2016-04       Impact factor: 12.300

7.  The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.

Authors:  Francesca Spinella; Valentina Caprara; Roberta Cianfrocca; Laura Rosanò; Valeriana Di Castro; Emirena Garrafa; Pier Giorgio Natali; Anna Bagnato
Journal:  Carcinogenesis       Date:  2014-01-28       Impact factor: 4.944

8.  Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury.

Authors:  Jie Lu; Jason M Frerich; L Christine Turtzo; Siqi Li; Jeffrey Chiang; Chunzhang Yang; Xiaoping Wang; Chao Zhang; Chenxi Wu; Zhongchan Sun; Gang Niu; Zhengping Zhuang; Roscoe O Brady; Xiaoyuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

9.  Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence.

Authors:  Fei Ye; Yibei Zhang; Yue Liu; Kazunari Yamada; Jonathan L Tso; Jimmy C Menjivar; Jane Y Tian; William H Yong; Dörthe Schaue; Paul S Mischel; Timothy F Cloughesy; Stanley F Nelson; Linda M Liau; William McBride; Cho-Lea Tso
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

Review 10.  Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.

Authors:  Fabio M Iwamoto; Adília Hormigo
Journal:  Front Oncol       Date:  2014-04-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.